Ultresa FDA Approval History
FDA Approved: Yes (Discontinued) (First approved March 1, 2012)
Brand name: Ultresa
Generic name: pancrelipase
Dosage form: Delayed Release Capsules
Company: Allergan plc
Treatment for: Pancreatic Exocrine Dysfunction
Marketing Status: Discontinued
Ultresa (pancrelipase) is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions.
Development Timeline for Ultresa
|Mar 1, 2012||Aptalis Pharma Announces FDA Approval of Ultresa (Pancrelipase) Delayed Release Capsules|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.